I have to ask after reading the economist report on AML, if Bisantrene was approved for use in France previously what would inhibit us from applying to reactivate use there again? I am guessing EU rules now but very interested to know.
Ann: Cancer Cell Journal Publication, page-122
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
-0.025(1.92%) |
Mkt cap ! $210.2M | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.30 | $1.27 | $19.48K | 15.26K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 155 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 370 | 1 |
View Market Depth
| Last trade - 12.02pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.27 |
Change
-0.025 ( 0.74 %) |
||||
| Open | High | Low | Volume | ||
| $1.27 | $1.29 | $1.27 | 1938 | ||
| Last updated 12.32pm 30/04/2024 ? | |||||
| RAC (ASX) Chart |